927 related articles for article (PubMed ID: 28548309)
21. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression.
Shi M; Bradner J; Hancock AM; Chung KA; Quinn JF; Peskind ER; Galasko D; Jankovic J; Zabetian CP; Kim HM; Leverenz JB; Montine TJ; Ginghina C; Kang UJ; Cain KC; Wang Y; Aasly J; Goldstein D; Zhang J
Ann Neurol; 2011 Mar; 69(3):570-80. PubMed ID: 21400565
[TBL] [Abstract][Full Text] [Related]
22. CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls.
Oosterveld LP; Verberk IMW; Majbour NK; El-Agnaf OM; Weinstein HC; Berendse HW; Teunissen CE; van de Berg WDJ
Mov Disord; 2020 Feb; 35(2):288-295. PubMed ID: 31737952
[TBL] [Abstract][Full Text] [Related]
23. REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson's disease: a cross-sectional and longitudinal study.
Nabizadeh F; Pirahesh K; Valizadeh P
J Neurol; 2022 Sep; 269(9):4836-4845. PubMed ID: 35426534
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal striatal dopamine transporter binding and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in Parkinson's disease.
Nabizadeh F; Pirahesh K; Ramezannezhad E
Neurol Sci; 2023 Feb; 44(2):573-585. PubMed ID: 36227385
[TBL] [Abstract][Full Text] [Related]
25. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.
Kang JH; Mollenhauer B; Coffey CS; Toledo JB; Weintraub D; Galasko DR; Irwin DJ; Van Deerlin V; Chen-Plotkin AS; Caspell-Garcia C; Waligórska T; Taylor P; Shah N; Pan S; Zero P; Frasier M; Marek K; Kieburtz K; Jennings D; Tanner CM; Simuni T; Singleton A; Toga AW; Chowdhury S; Trojanowski JQ; Shaw LM;
Acta Neuropathol; 2016 Jun; 131(6):935-49. PubMed ID: 27021906
[TBL] [Abstract][Full Text] [Related]
26. Cerebrospinal Fluid Cytokines and Neurodegeneration-Associated Proteins in Parkinson's Disease.
Wijeyekoon RS; Moore SF; Farrell K; Breen DP; Barker RA; Williams-Gray CH
Mov Disord; 2020 Jun; 35(6):1062-1066. PubMed ID: 32413185
[TBL] [Abstract][Full Text] [Related]
27. Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease.
Ibanez L; Bahena JA; Yang C; Dube U; Farias FHG; Budde JP; Bergmann K; Brenner-Webster C; Morris JC; Perrin RJ; Cairns NJ; O'Donnell J; Álvarez I; Diez-Fairen M; Aguilar M; Miller R; Davis AA; Pastor P; Kotzbauer P; Campbell MC; Perlmutter JS; Rhinn H; Harari O; Cruchaga C; Benitez BA
Acta Neuropathol Commun; 2020 Nov; 8(1):196. PubMed ID: 33213513
[TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders.
Hall S; Janelidze S; Surova Y; Widner H; Zetterberg H; Hansson O
Sci Rep; 2018 Sep; 8(1):13276. PubMed ID: 30185816
[TBL] [Abstract][Full Text] [Related]
29. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.
Majbour NK; Vaikath NN; van Dijk KD; Ardah MT; Varghese S; Vesterager LB; Montezinho LP; Poole S; Safieh-Garabedian B; Tokuda T; Teunissen CE; Berendse HW; van de Berg WD; El-Agnaf OM
Mol Neurodegener; 2016 Jan; 11():7. PubMed ID: 26782965
[TBL] [Abstract][Full Text] [Related]
30. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
31. Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study.
Brockmann K; Schulte C; Deuschle C; Hauser AK; Heger T; Gasser T; Maetzler W; Berg D
Parkinsonism Relat Disord; 2015 Dec; 21(12):1427-34. PubMed ID: 26475624
[TBL] [Abstract][Full Text] [Related]
32. Low soluble amyloid-β 42 is associated with smaller brain volume in Parkinson's disease.
Espay AJ; Lafontant DE; Poston KL; Caspell-Garcia C; Marsili L; Cho HR; McDaniel C; Kim N; Coffey CS; Mahajan A; Ezzat K; Sturchio A;
Parkinsonism Relat Disord; 2021 Nov; 92():15-21. PubMed ID: 34656902
[TBL] [Abstract][Full Text] [Related]
33. Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels.
Ibanez L; Dube U; Saef B; Budde J; Black K; Medvedeva A; Del-Aguila JL; Davis AA; Perlmutter JS; Harari O; Benitez BA; Cruchaga C
BMC Neurol; 2017 Nov; 17(1):198. PubMed ID: 29141588
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-1β, interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor-α levels in CSF and serum in relation to the clinical diversity of Parkinson's disease.
Karpenko MN; Vasilishina AA; Gromova EA; Muruzheva ZM; Miliukhina IV; Bernadotte A
Cell Immunol; 2018 May; 327():77-82. PubMed ID: 29478949
[TBL] [Abstract][Full Text] [Related]
35. CSF α-synuclein, tau, and amyloid β in Parkinson's disease.
Shi M; Zhang J
Lancet Neurol; 2011 Aug; 10(8):681; author's reply 681-3. PubMed ID: 21777821
[No Abstract] [Full Text] [Related]
36. Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.
Mollenhauer B; Caspell-Garcia CJ; Coffey CS; Taylor P; Shaw LM; Trojanowski JQ; Singleton A; Frasier M; Marek K; Galasko D;
Neurology; 2017 Nov; 89(19):1959-1969. PubMed ID: 29030452
[TBL] [Abstract][Full Text] [Related]
37. Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease.
Buddhala C; Campbell MC; Perlmutter JS; Kotzbauer PT
Neurobiol Aging; 2015 Jan; 36(1):476-84. PubMed ID: 25212463
[TBL] [Abstract][Full Text] [Related]
38. CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report.
Gao R; Zhang G; Chen X; Yang A; Smith G; Wong DF; Zhou Y
PLoS One; 2016; 11(10):e0164762. PubMed ID: 27764160
[TBL] [Abstract][Full Text] [Related]
39. Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer's and Parkinson's Diseases in Young Mexico City Residents.
Calderón-Garcidueñas L; Avila-Ramírez J; Calderón-Garcidueñas A; González-Heredia T; Acuña-Ayala H; Chao CK; Thompson C; Ruiz-Ramos R; Cortés-González V; Martínez-Martínez L; García-Pérez MA; Reis J; Mukherjee PS; Torres-Jardón R; Lachmann I
J Alzheimers Dis; 2016 Sep; 54(2):597-613. PubMed ID: 27567860
[TBL] [Abstract][Full Text] [Related]
40. CSF β-amyloid
Kim R; Lee J; Kim HJ; Kim A; Jang M; Jeon B; Kang UJ
Neurology; 2019 Jan; 92(1):e40-e47. PubMed ID: 30504429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
